23andMe Aims to Use Genetic Data to Develop Drugs

In a big shift of focus, the personal genomics company 23andMe recently announced the creation of a new therapeutics group with the intention of developing new therapies for both common and rare diseases.

23andMe

kwiKBio Aims to Fast Track Research with Crowdsourcing Campaign

kwiKBio believes it’s taking too long to solve diseases and create cures. The company aims to combine advanced semantic web bioinformatics with contract research organization (CRO) business development in an e-commerce biomedical research portal. Think Wikipedia with an interactive research component coupled with Expedia for purchasing a ticket to a laboratory test.

kwikBio

Biomarker Bulletin: October 10, 2011

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons

 

Biomarker Bulletin: April 19, 2011

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons

Health Highlights – July 10th, 2007

Health Highlights is a biweekly summary of particularly interesting articles from credible sources of health and medical information that we follow & read. For a complete list of recommeded sources, see our links page.

Health Highlights